Schackman, Bruce RHaas, David WPark, Sanghee SLi, X CynthiaFreedberg, Kenneth2016-05-022016Schackman, Bruce R, David W Haas, Sanghee S Park, X Cynthia Li, and Kenneth A Freedberg. 2016. “Cost–effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.” Pharmacogenomics 16 (18): 2007-2018. doi:10.2217/pgs.15.142. http://dx.doi.org/10.2217/pgs.15.142.1462-2416http://nrs.harvard.edu/urn-3:HUL.InstRepos:26860273Aims To assess the cost–effectiveness of CYP2B6 genotyping to guide efavirenz dosing for initial HIV therapy in the USA. Methods: We used the Cost–Effectiveness of Preventing AIDS Complications (CEPAC) microsimulation model to project quality-adjusted life expectancy and lifetime costs (2014 US dollars) for efavirenz-based HIV therapy with or without CYP2B6 genotyping. We assumed that with genotyping 60% of patients would be eligible to receive lower doses. Results: Current care without CYP2B6 genotyping has an incremental cost–effectiveness ratio >$100,000/QALY compared with genotype-guided dosing, even if lower dosing reduces efficacy. When we assumed generic efavirenz availability, conclusions were similar unless lower dosing reduces efficacy by 6% or more. Conclusion: CYP2B6 genotyping can inform efavirenz dosing and decrease HIV therapy cost.en-USantiretroviral therapycost–effectivenessdose optimizationgenotypingHIVJournal Article2016-05-0210.2217/pgs.15.142